Were Analysts Bearish Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) This Week?

This stock is ahead of its 52-week low with +43.98%. About 179,752 shares traded.

In recent action, Bellicum Pharmaceuticals, Inc. It has outperformed by 104.70% the S&P500. (BLCM) now trades with a market capitalization of $394.39 Million. After this sale, 777,255 common shares of BLCM are directly owned by the insider, with total stake valued at $10,866,025. (NYSE:TXMD) has been 3.47 million shares per day over the past 30 days. In our current pick, Bellicum Pharmaceuticals, Inc. 2,776,731 shares of the stock traded hands.

Bellicum Pharmaceuticals, Inc. (BLCM)'s Bullish picture have been built after taking the consideration of last five trading activity. The Piotroski F-Score of Bellicum Pharmaceuticals, Inc.

Generally the investors keep monitoring the performance of the companies in the stock markets and they use technical indicators to carry out a technical stock analysis that would predict the average true ranges of various firms. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. A negative earnings surprise will usually result in a decline in share price. It's proprietary chemical induction of dimerization technology engineers and controls components of the immune system.

On Monday, Shares of Bellicum Pharmaceuticals Inc (NASDAQ:BLCM), inclined 13.86% and closed at $12.90 in the last trading session. Therefore 78% are positive.

Bellicum Pharmaceuticals, Inc.'s average Book Value per Share Growth Rate was -16.4 percent during the past 12 months. The firm earned "Sell" rating on Monday, September 21 by Zacks. "ADVISORS LP Buy 166666 shares of the company at a price of $12 on 2017-03-24".

06/02/2016 - SunTrust began new coverage on Bellicum Pharmaceuticals, Inc. giving the company a " rating.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has accumulated 27.9% over the course of one week. They issued an "outperform" rating and a $29.50 price target on the stock. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.17 average brokerage recommendation. The rating was initiated by Cantor Fitzgerald with "Buy" on Wednesday, November 2. Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has risen 32.63% since June 23, 2016 and is uptrending. The rating was downgraded by Zacks to "Hold" on Wednesday, August 19.

Price to Earning P/E ratio and Forward P/E stand at 0 and 0 respectively. It worsened, as 64 investors sold AMAT shares while 272 reduced holdings.

Several analysts have issued reports on BLCM shares. (NASDAQ:AMAT). Boothbay Fund Management Ltd Liability Corporation has 36,577 shares. On the other end, a stock with a score from 0-2 would be viewed as weak. (NASDAQ:AMAT). First Financial In stated it has 750 shares. (NASDAQ:BLCM) higher to the next line of resistance at $15.01 a share. The rating was initiated by SunTrust on Friday, June 3 with "Buy". The ROIC 5 year average of Ra Pharmaceuticals, Inc. Applied Materials Inc. had 69 analyst reports since August 4, 2015 according to SRatingsIntel. As per Tuesday, January 17, the company rating was upgraded by Goldman Sachs. Citigroup has "Neutral" rating and $24 target. The firm has "Buy" rating given on Thursday, October 1 by Canaccord Genuity. The stock's market capitalization is 426.37M. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. BLCM is down around 30.54% from its 12-month high of $9.71 notched on Jun 12, 2017 but is -65.31% above its highest point the past 12 months of $23.11 a share. The firm has "Sector Perform" rating given on Friday, May 20 by RBC Capital Markets. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals, Inc. with MarketBeat.com's FREE daily email newsletter.

  • Zachary Reyes